Elevra Lithium Limited · ASX:ELV
Elevra Lithium — Shareholder Meeting (November 2026)
32 slides from Elevra Lithium's shareholder meeting presentation, Nov 19, 2026
Slide 1: 2026 Annual General Meeting Chair Address and MD/CEO Presentation
ASX ANNOUNCEMENT 19 November 2026 For personal use only 2026 Annual General Meeting Chair Address and MD/CEO Presentation Good morning ladies and gentlemen, shareholders, and esteemed guests. My name is Dawne Hickton, the Chair of Elevra Lithium Limited. On behalf of my fellow Directors, it is my pl
Slide 2: Chair Address (continued)
schedule rather than pacing our investment around future financing events. It also funds the technical and pre-development work at Moblan through to a Final Investment Decision. At Moblan, we took another step forward there. We acquired the offtake rights over Moblan that had been granted to a third
Slide 3: Chair Address (continued) and About Elevra Lithium
exercise objective judgement, challenge management constructively, and act in the interests of all shareholders. Second, we wanted to keep the right mix of skills and diversity of experience at the table. We need directors with operating, technical, financial and capital markets experience, along wit
Slide 4: Elevra Lithium 2026 Annual General Meeting
rsonal use only Elevra Lithium 2026 Annual General Meeting Thursday, 19 November 2026 ASX:ELV • NASDAQ:ELVR
Slide 5: 2026 AGM Agenda
2026 AGM Agenda rsonal use only 01 Chair’s Address 02 Meeting Procedures 03 Resolutions, Proxies and Voting 04 Managing Director & CEO Presentation 05 Questions ELEVRA LITHIUM 2
Slide 6: Chair's Address
rsonal use only 01 Chair’s Address Dawne Hickton
Slide 7: FY26 Strategic Accomplishments
FY26 Strategic Accomplishments Resetting the corporate foundation Advancing the project pipeline rsonal use only Merger completed1 NAL Brownfield Expansion scoping complete5 Completed the merger between Sayona Mining and Piedmont Lithium, Evaluated expansion opportunities and completed Scoping Studi
Slide 8: Portfolio Optimisation
Portfolio Optimisation Divesting non-core assets to concentrate on North American development rsonal use only US$71m A$16m 4 Ewoyaa sale completed1 Tabba Tabba tenement sold2 WA projects proposed for the Morella Lithium JV3 Outcome Consideration from Wildcat Proposed terms (non-binding) • Sold all r
Slide 9: Board of Directors
Board of Directors A Majority Independent and Diverse Board Board of Directors Current Post 2026 AGM1 rsonal use only Independence 25% 33% Independent > 67% Non-Independent 75% Dawne Hickton Lucas Dow James Brown Christina Alvord Chair & Non-Exec. Director Managing Director & CEO Non-Executive Direc
Slide 10: Meeting Procedures
rsonal use only 02 Meeting Procedures
Slide 11: How to ask a question
How to ask a question rsonal use only • To ask a question, select the “Q&A” icon • Select the topic of your question related to from the drop-down list • Type your question in the text box and press the “send” button • To ask a verbal question, follow the instructions below the broadcast window ELEV
Slide 12: How to vote
How to vote rsonal use only • When the poll is open, select the “Vote” icon at the top of the screen • To vote, select either “For”, “Against” or “Abstain” • You will see a vote confirmation • To change or cancel your vote, “Click here to change your vote” at any time until the poll is closed ELEVRA
Slide 13: Resolutions, Proxies and Voting
rsonal use only 03 Resolutions, Proxies and Voting
Slide 14: Adoption of Remuneration Report
Resolution 1 Adoption of Remuneration Report rsonal use only To consider and, if thought fit, pass the following non-binding resolution as an ordinary resolution: “That, for the purposes of section 250R(2) of the Corporations Act, the Remuneration Report for the year ended 30 June 2026 is adopted.”
Slide 15: Re-election of Director – James Brown
Resolution 2 Re-election of Director – James Brown rsonal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That Mr. James Brown who retires by rotation in accordance with rule 7.1(d) of the Constitution and ASX Listing Rule 14.4, and being eligible,
Slide 16: Grant of STI Performance Rights to the MD and CEO
Resolution 3 Grant of STI Performance Rights to the Managing Director and CEO rsonal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of 56,558 STI Performance
Slide 17: Grant of LTI Performance Rights to the MD and CEO
Resolution 4 Grant of LTI Performance Rights to the Managing Director and CEO rsonal use only To consider and, if thought fit, pass the following resolution as an ordinary resolution: “That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of 140,050 LTI Performance
Slide 18: Managing Director & CEO Presentation
rsonal use only 04 Managing Director & CEO Presentation Lucas Dow
Slide 19: FY26 Highlights
FY26 Highlights FY26 strengthened NAL’s operating platform, improved safety and operational resilience, and established the foundation for a fully funded expansion rsonal use only Operations Financial Corporate 197,967 $202M Merger between • Dual listed on ASX and Nasdaq with ability to convert hold
Slide 20: The Elevra Strategy
The Elevra Strategy Disciplined delivery remains central to our strategy rsonal use only 01 02 03 Optimise Existing Operations Develop Assets Following Integrate into the Supply Chain Expanded Resource Base Via Strategic Partnerships Focused on optimising production sustainably Deliver portfolio pot
Slide 21: Commercial Strategy
Commercial Strategy Targeting a diversified, market-linked and flexible sales portfolio as NAL volumes expand 01 Strategic Offtake 02 Market-Based Pricing 03 Commercial rsonal use only Partnerships Framework Flexibility • Targeting 2-3 core offtake customers • Spot-linked pricing using recognised •
Slide 22: FY26 Health and Safety Performance
FY26 Health and Safety Performance Safety performance materially improved, reinforcing a strong operating culture Safety performance strengthened alongside rsonal use only increased operational activity, providing a stronger TRIFR Per Million Work Hours1,2 foundation for the NAL expansion • Signific
Slide 23: Operational Performance
Operational Performance Resilient operating performance despite temporary mining constraints rsonal use only Delivering within revised FY26 guidance NAL Production & Unit Operating Costs 100,000 FY26 FY26 FY26 UOM Guidance Guidance Actual 1,000 (revised)1 (initial)1 90,000 894 907 Production Metrics
Slide 24: Strategic Financing Package
Strategic Financing Package Secured funding to accelerate near-term growth and advance growth initiatives1 rsonal use only Accelerating NAL Funding Certainty Enhanced Balance Sheet Continued Focus on Expansion Delivery Flexibility Growth Initiatives • Brings forward incremental • Timely funding cert
Slide 25: NAL Expansion Transforms Elevra into a Larger, Lower Cost Producer
NAL Expansion Transforms Elevra into a Larger, Lower Cost Producer Expanded output and lower unit costs create a pathway to improved cash flow generation Average Annual NAL Production Capacity Long-term value creation rsonal use only Strengthens NAL’s position as a Average LOM SC5.4 (post expansion)
Slide 26: Near-Term Lithium Market Weakness
Near-Term Lithium Market Weakness Declines in Chinese lithium carbonate futures have pulled prices lower contrary to falling inventories rsonal use only Lithium price weakness appears Spodumene Concentrate 6% Price GFEX Lithium Carbonate Futures driven by sentiment US$/t, CIF China January 2027 Lith
Slide 27: Supportive Demand Outlook into 2030
Supportive Demand Outlook into 2030 Demand growth presents opportunity for development projects rsonal use only Medium-term demand outlook Broker Outlook Global Lithium Demand remains strong Spodumene Concentrate 6% Price, US$/t Mt LCE $2,400 4.0 • Lithium demand is forecast to approximately double
Slide 28: FY27 Guidance
FY27 Guidance rsonal use only FY26 Actual FY27 Guidance Additional Information Spodumene 197,967 198,000 – 210,000 • SC 5.2% product grade Concentrate dmt dmt • 100% NAL production Production Spodumene • SC 5.2% product grade 181,494 200,000 – 230,000 Concentrate • Volumes modestly front-weighted (5
Slide 29: Questions?
rsonal use only 05 Questions?
Slide 30: Thank You for Attending
Thank You for rsonal use only Attending
Slide 31: Appendix
rsonal use only Appendix
Slide 32: Supporting Data: Lithium Market Outlook
Supporting Data Lithium Market Outlook rsonal use only Spodumene Concentrate Est. Global Lithium Demand Est. 2026 2027 2028 2029 2030 2026 2027 2028 2029 2030 6% Price (US$/t) Date (kt LCE) Date Broker 1 Oct-26 2,012 2,043 2,048 1,785 1,680 Broker 1 Oct-26 2,108 2,324 2,510 2,634 2,750 Broker 2 Oct-